Home / Author Archives: bio972 (page 2)

Author Archives: bio972

Doctors at Rambam Hospital Implant 3-D Printed Jaw in Wounded Syrian Man לסת שהודפסה במדפסת תלת-ממד הושתלה בפצוע סורי בבית החולים רמב״ם

Rambam Medical Center in Haifa has announced the successful implantation of a 3D-printed titanium jaw in a 23-year-old Syrian man after a bullet from his country’s civil war had left his completely destroyed. Ashdod-based AB Dental provided the metal “bone” at ...

Read More »

Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications כן פייט ביופרמה מכריזה על אבני דרך לתרופות ב-4 אינדיקציות

Can-Fite BioPharma Ltd., an advanced clinical stage drug development company, announced its anticipated clinical milestones for 2015. Plans for Q1 include positive results to be released from a Phase II/III psoriasis trial for its lead drug candidate, CF101, and a commercial ...

Read More »

Chiasma Raising Millions Despite Roche Collaboration Debacle כיאזמה גייסה מיליוני דולרים למרות קריסתו של שיתוף הפעולה המתוכנן עם רוש

Jerusalem-based Chiasma has raised $33.8 million of a proposed $56.3 million round, despite cancellation of an approximately $595 million deal with global biotech Roche last summer. New funds were provided by a portfolio of investors including MPM Capital, Abingworth, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures. Chiasma has shown promise as a ...

Read More »

Integrity Applications, Inc. Announces Completion Of Successful $8.5 Million Equity Financing אינטגריטי אפליקיישנס בע"מ מכריז על השלמת גיוס מוצלח של $8.5 מיליון הון העצמי

Integrity Applications, Inc., developer of the GlucoTrack noninvasive blood glucose monitor, has raised $1,647,450 through a private sale of 1,647.45 ‘units’ of preferred stock and stock options. The company has raised a total of $8.5 million through the sale of 8,500 ‘units’ ...

Read More »

Mazor Robotics Reports Orders for Six Renaissance Systems During the Fourth Quarter of 2014 מזור רובוטיקה מדווחת על הזמנות לשש מערכות רנסנס במהלך הרבעון הרביעי של 2014

Mazor Robotics Ltd., developer of robotic surgical guidance systems, announced that the company received six orders for Renaissance spine surgery systems in fourth quarter 2014. Completion of these agreements did not occur by the end of the year and as a ...

Read More »

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets קומפיוג’ן: תוצאות ניסוייות חיוביות עבור 2 מ-5 חלבוני מטרה פוטנציאליים

Compugen, a drug discovery company that uses computational biology to predict and select product candidates, announced positive initial experimental results for the first two of five in silico-predicted targets for antibody drug conjugate (ADC) cancer therapy disclosed in late 2013. ...

Read More »

RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015 התחזית העסקית ואבני הדרך הצפוי של רדהיל ביופרמה ב2015

RedHill BioPharma Ltd., a biopharmaceutical company focused on the development and acquisition of late clinical-stage orally administered drugs for treating inflammatory and gastrointestinal diseases, announced selected key milestones and events anticipated in 2015. Upcoming milestones include: Top-line data from ongoing first Phase III study ...

Read More »

BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™ בריינסטורם מכריז על מחקר שהראה שנור-און מועיל קלינית לכמעט כל החולים

BrainStorm Cell Therapeutics Inc. announced positive results in its Phase IIa clinical trial of its NurOwn stem cell therapy technology for amyotrophic lateral sclerosis (ALS). 92% of the 14 subjects enrolled at Hadassah Medical Center experienced an improvement in the rate of ALS ...

Read More »

Protalix BioTherapeutics Announces New Strategy for Accelerated Growth פרוטליקס מכריז על אסטרטגיה חדשה לצמיחה מואצת

Protalix Biotherapeutics, a biopharmaceutical company focused on developing recombinant therapeutic proteins expressed through its plant cell-based expression system, is prioritizing pipeline candidates to focus on bio-better products with a clear competitive advantage. Therapeutic areas of focus will include Fabry disease, inflammatory bowel disease, ...

Read More »

NeuroDerm Share Prices Soar After Positive Results in Phase IIa Parkinson’s Trial המניה של נוירודרם הוכפל לאור תוצאות ניסוי לטיפול בפרקינסון

Rehovot-based NeuroDerm Ltd. (NASDAQ: NDRM) ended 2014 on a high note as it saw its share price more than double following announcement of positive results in a Phase IIa Parkinson’s drug trial. According to the company, administration of a continuous subcutaneous high-level dose of ...

Read More »